|
1
|
Wang GL, Jiang BH, Rue EA and Semenza GL:
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS
heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci
USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wiesener MS, Turley H, Allen WE, et al:
Induction of endothelial PAS domain protein-1 by hypoxia:
Characterization and comparison with hypoxia-inducible
factor-1alpha. Blood. 92:2260–2268. 1998.PubMed/NCBI
|
|
3
|
Heidbreder M, Fröhlich F, Jöhren O, et al:
Hypoxia rapidly activates HIF-3alpha mRNA expression. FASEB J.
17:1541–1543. 2003.PubMed/NCBI
|
|
4
|
Li QF, Wang XR, Yang YW and Lin H: Hypoxia
upregulates hypoxia-inducible factor (HIF)-3alpha expression in
lung epithelial cells: Characterization and comparison with
HIF-1alpha. Cell Res. 16:548–558. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pugh CW, O'Rourke JF, Nagao M, et al:
Activation of hypoxia-inducible factor-1; definition of regulatory
domains within the alpha subunit. J Biol Chem. 272:11205–11214.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ikeda E, Achen MG, Breier G and Risau W:
Hypoxia-induced transcriptional activation and increased mRNA
stability of vascular endothelial growth factor in C6 glioma cells.
J Biol Chem. 270:19761–19766. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Forsythe JA, Jiang BH, Iyer NV, et al:
Activation of vascular endothelial growth factor gene transcription
by hypoxia-inducible factor 1. Mol Cell Biol. 16:4604–4613.
1996.PubMed/NCBI
|
|
8
|
Takeda N, Maemura K, Imai Y, et al:
Endothelial PAS domain protein 1 gene promotes angiogenesis through
the transactivation of both vascular endothelial growth factor and
its receptor, Flt-1. Circ Res. 95:146–153. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gerber HP, Condorelli F, Park J and
Ferrara N: Differential transcriptional regulation of the two
vascular endothelial growth factor receptor genes. Flt-1, but not
Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem.
272:23659–23667. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Marti HH and Risau W: Systemic hypoxia
changes the organ-specific distribution of vascular endothelial
growth factor and its receptors. Proc Natl Acad Sci USA.
95:15809–15814. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Semenza GL and Wang GL: A nuclear factor
induced by hypoxia via de novo protein synthesis binds to the human
erythropoietin gene enhancer at a site required for transcriptional
activation. Mol Cell Biol. 12:5447–5454. 1992.PubMed/NCBI
|
|
12
|
Kertesz N, Wu J, Chen TH, et al: The role
of erythropoietin in regulating angiogenesis. Dev Biol.
276:101–110. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jaquet K, Krause K, Tawakol-Khodai M,
Geidel S and Kuck KH: Erythropoietin and VEGF exhibit equal
angiogenic potential. Microvasc Res. 64:326–333. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Morita M, Ohneda O, Yamashita T, et al:
HLF/HIF-2alpha is a key factor in retinopathy of prematurity in
association with erythropoietin. EMBO J. 22:1134–1146. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hirota K and Semenza GL: Regulation of
angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol.
59:15–26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yu J, de Muinck ED, Zhuang Z, et al:
Endothelial nitric oxide synthase is critical for ischemic
remodeling, mural cell recruitment, and blood flow reserve. Proc
Natl Acad Sci USA. 102:10999–11004. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coulet F, Nadaud S, Agrapart M and
Soubrier F: Identification of hypoxia-response element in the human
endothelial nitric-oxide synthase gene promoter. J Biol Chem.
278:46230–46240. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhao X, Lu X and Feng Q: Deficiency in
endothelial nitric oxide synthase impairs myocardial angiogenesis.
Am J Physiol Heart Circ Physiol. 283:H2371–H2378. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maynard MA, Qi H, Chung J, et al: Multiple
splice variants of the human HIF-3 alpha locus are targets of the
von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem.
278:11032–11040. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Strauss L, Volland D, Kunkel M and
Reichert TE: Dual role of VEGF family members in the pathogenesis
of head and neck cancer (HNSCC): Possible link between angiogenesis
and immune tolerance. Med Sci Monit. 11:BR280–BR292.
2005.PubMed/NCBI
|
|
21
|
Alon T, Hemo I, Itin A, Pe'er J, Stone J
and Keshet E: Vascular endothelial growth factor acts as a survival
factor for newly formed retinal vessels and has implications for
retinopathy of prematurity. Nat Med. 1:1024–1028. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gerber HP, Dixit V and Ferrara N: Vascular
endothelial growth factor induces expression of the antiapoptotic
proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem.
273:13313–13316. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gerber HP, McMurtrey A, Kowalski J, et al:
Vascular endothelial growth factor regulates endothelial cell
survival through the phosphatidylinositol 3′-kinase/Akt signal
transduction pathway. Requirement for Flk-1/KDR activation. J Biol
Chem. 273:30336–30343. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Benjamin LE, Golijanin D, Itin A, Pode D
and Keshet E: Selective ablation of immature blood vessels in
established human tumors follows vascular endothelial growth factor
withdrawal. J Clin Invest. 103:159–165. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yuan F, Chen Y, Dellian M, Safabakhsh N,
Ferrara N and Jain RK: Time-dependent vascular regression and
permeability changes in established human tumor xenografts induced
by an anti-vascular endothelial growth factor/vascular permeability
factor antibody. Proc Natl Acad Sci USA. 93:14765–14770. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Scrideli CA, Carlotti CG Jr, Okamoto OK,
et al: Gene expression profile analysis of primary glioblastomas
and non-neoplastic brain tissue: Identification of potential target
genes by oligonucleotide microarray and real-time quantitative PCR.
J Neurooncol. 88:281–291. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Borel F, Han R, Visser A, Petry H, van
Deventer SJ, Jansen PL and Konstantinova P: Réseau Centre de
Ressources Biologiques Foie (French Liver Biobanks Network),
France: Adenosine triphosphate-binding cassette transporter genes
up-regulation in untreated hepatocellular carcinoma is mediated by
cellular microRNAs. Hepatology. 55:821–832. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
International Union Against Cancer: Head
and Neck Tumours. In: TNM Classification of Malignant Tumours
(7th). Sobin LH, Gospodarowicz MK and Wittekind C: Wiley-Blackwell.
39–46. 2009.
|
|
30
|
Moreno-Galindo C, Hermsen M,
Garcia-Pedrero JM, Fresno MF, Suarez C and Rodrigo JP: p27 and BCL2
expression predicts response to chemotherapy in head and neck
squamous cell carcinomas. Oral Oncol. 50:128–134. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wachters JE, Schrijvers ML,
Slagter-Menkema L, Mastik M, de Bock GH, Langendijk JA, et al:
Prognostic significance of HIF-1a, CA-IX, and OPN in T1-T2
laryngeal carcinoma treated with radiotherapy. Laryngoscope.
123:2154–2160. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Li DW, Dong P, Wang F, Chen XW, Xu CZ and
Zhou L: Hypoxia induced multidrug resistance of laryngeal cancer
cells via hypoxia-inducible factor-1α. Asian Pac J Cancer Prev.
14:4853–4858. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xie J, Li DW, Chen XW, Wang F and Dong P:
Expression and significance of hypoxia-inducible factor-1α and
MDR1/P-glycoprotein in laryngeal carcinoma tissue and hypoxic Hep-2
cells. Oncol Lett. 6:232–238. 2013.PubMed/NCBI
|
|
34
|
Wu XH, Chen SP, Mao JY, Ji XX, Yao HT and
Zhou SH: Expression and significance of hypoxia-inducible factor-1α
and glucose transporter-1 in laryngeal carcinoma. Oncol Lett.
5:261–266. 2013.PubMed/NCBI
|
|
35
|
Li DW, Zhou L, Jin B, Xie J and Dong P:
Expression and significance of hypoxia-inducible factor-1α and
survivin in laryngeal carcinoma tissue and cells. Otolaryngol Head
Neck Surg. 148:75–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Douglas CM, Bernstein JM, Ormston VE, et
al: Lack of prognostic effect of carbonic anhydrase-9, hypoxia
inducible factor-1α and bcl-2 in 286 patients with early squamous
cell carcinoma of the glottic larynx treated with radiotherapy.
Clin Oncol (R Coll Radiol). 25:59–65. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wu XH, Lu YF, Hu XD, Mao JY, Ji XX, Yao
HT, et al: Expression of hypoxia inducible factor-1α and its
significance in laryngeal carcinoma. J Int Med Res. 38:2040–2046.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Moon SY, Chang HW, Roh JL, et al: Using
YC-1 to overcome the radioresistance of hypoxic cancer cells. Oral
Oncol. 45:915–919. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cabanillas R, Rodrigo JP, Secades P, et
al: The relation between hypoxia-inducible factor (HIF)-1alpha
expression with p53 expression and outcome in surgically treated
supraglottic laryngeal cancer. J Surg Oncol. 99:373–378. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wildeman MA, Gibcus JH, Hauptmann M, et
al: Radiotherapy in laryngeal carcinoma: can a panel of 13 markers
predict response? Laryngoscope. 119:316–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kyzas PA, Stefanou D, Batistatou A and
Agnantis NJ: Hypoxia-induced tumor angiogenic pathway in head and
neck cancer: an in vivo study. Cancer Lett. 225:297–304. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Yu L, Liu Y and Cui Y: Expression of
hypoxia inducible factor-1alpha and its relationship to apoptosis
and proliferation in human laryngeal squamous cell carcinoma. J
Huazhong Univ Sci Technolog Med Sci. 24:636–638. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Keith B, Johnson RS and Simon MC: HIF1α
and HIF2α: Sibling rivalry in hypoxic tumour growth and
progression. Nat Rev Cancer. 12:9–22. 2012.
|
|
44
|
Holmquist-Mengelbier L, Fredlund E,
Löfstedt T, et al: Recruitment of HIF-1alpha and HIF-2alpha to
common target genes is differentially regulated in neuroblastoma:
HIF-2alpha promotes an aggressive phenotype. Cancer Cell.
10:413–423. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Koh MY, Lemos R Jr, Liu X and Powis G: The
hypoxia-associated factor switches cells from HIF-1α- to
HIF-2α-dependent signaling promoting stem cell characteristics,
aggressive tumor growth and invasion. Cancer Res. 71:4015–4027.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Koh MY and Powis G: Passing the baton: The
HIF switch. Trends Biochem Sci. 37:364–372. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Raval RR, Lau KW, Tran MG, Sowter HM,
Mandriota SJ, Li JL, Pugh CW, Maxwell PH, Harris AL and Ratcliffe
PJ: Contrasting properties of hypoxia-inducible factor 1 (HIF-1)
and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol
Cell Biol. 25:5675–5686. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mandriota SJ, Turner KJ, Davies DR, et al:
HIF activation identifies early lesions in VHL kidneys: Evidence
for site-specific tumor suppressor function in the nephron. Cancer
Cell. 1:459–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Fong GH: Mechanisms of adaptive
angiogenesis to tissue hypoxia. Angiogenesis. 11:121–140. 2008.
View Article : Google Scholar : PubMed/NCBI
|
